ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported strong growth in neffy prescriptions and revenue, with a 2.5-fold increase in U.S. net product revenue. Despite a net loss, the financial health remains stable with significant cash reserves. The Q&A highlighted positive feedback from new initiatives and optimism about future growth through partnerships and expanded market access. While some uncertainties exist, such as reliance on a term loan and inconsistent institutional sales, the overall sentiment is positive due to revenue growth, strategic initiatives, and optimistic guidance.
Key Financial Performance
U.S. net product revenue for neffy $31.3 million in Q3, representing a 2.5-fold increase from the prior quarter. This change reflects the strong growth in new patient starts and overall demand for neffy.
Total revenue $32.5 million in Q3, including $31.3 million from U.S. net product revenue, $1.1 million in supply revenue from partners, and $0.1 million in royalties from ALK related to EURneffy in Germany.
R&D expenses $2.8 million in Q3, primarily related to the ongoing Phase IIb urticaria trial and continued development expenses for neffy.
SG&A expenses $74.8 million in Q3, reflecting ongoing investment in the national DTC campaign and sales and marketing efforts. These are deliberate investments designed to drive durable share growth.
Net loss $51.2 million or $0.52 per share in Q3.
Cash, cash equivalents, and short-term investments $288.2 million as of September 30, 2025, supported by a $100 million draw from a $250 million term loan facility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Neffy Revenue Growth: U.S. net product revenue for Neffy reached $31.3 million in Q3, a 2.5-fold increase from the prior quarter, driven by strong growth in new patient starts and demand.
Real-World Outcomes: Findings from the Neffy Experience Program showed that 9 out of 10 patients experiencing anaphylaxis were effectively treated with a single dose of Neffy, comparable to epinephrine injections.
New Initiatives: Launched 'Get Neffy on Us' program to simplify access and prescriptions, aiming to accelerate sales growth year-round.
Global Expansion: Neffy launched in Germany in June with rapid market share growth. Approval in Japan was received in September, with launches in Canada and China expected in 2026.
Market Dynamics: Back-to-school seasonality caused a temporary pause in market share growth in Q3, but growth resumed in Q4. The epinephrine market is valued at $2 billion annually, growing at 6%-8%.
Operational Efficiency: Improved gross-to-net retention with cash prescriptions decreasing from 20% to 12%, enhancing profitability.
DTC Campaign Impact: Consumer awareness increased from 20% to 56%, with 80% of surveyed patients likely to ask their healthcare provider about Neffy.
Strategic Financing: Secured a $250 million term loan facility, drawing $100 million to support Neffy’s commercial growth and maintain a strong balance sheet.
Market Expansion Strategy: Investments are focused on expanding the epinephrine market, improving adherence, and converting the $2 billion U.S. market to Neffy’s net price.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
IQVIA data inaccuracies: The weekly IQVIA rapid data does not accurately reflect neffy's true performance or market share due to exclusion of certain retail, mail order, specialty pharma volumes, and bulk purchases by institutions and clinics. This creates challenges in tracking and predicting sales performance.
Back-to-school seasonality: During the back-to-school season, allergists and pediatricians have limited time for appointments, reducing opportunities to discuss new treatment options or change prescriptions. This led to a temporary pause in market share growth in Q3.
Seasonal sales decline: Q4 sales are anticipated to decrease from Q3 due to the overall epinephrine market typically declining by about 1/3 during the holiday season.
Administrative burdens in the U.S.: Administrative barriers, such as prior authorizations and paperwork, hinder the prescribing process for neffy in the U.S., slowing market share growth compared to countries like Germany with more seamless prescribing systems.
High SG&A expenses: Significant investments in direct-to-consumer campaigns and sales efforts have increased SG&A expenses, which could pressure profitability if revenue growth does not keep pace.
Need for real-world evidence: Continued investment in generating and disseminating real-world evidence is required to validate neffy's effectiveness and support its adoption, which could delay broader acceptance.
Economic uncertainties: The company relies on a $250 million term loan facility to fund commercial growth, which could pose financial risks if market conditions or sales performance deteriorate.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: Q4 sales are expected to decrease from Q3 due to seasonality and holidays, but quarter-over-quarter growth is anticipated to resume in 2026 as market share and prescription volumes rise.
Global Expansion: Neffy is expected to launch in Japan in Q4 2025, with approvals in Canada and China anticipated in the first half of 2026. These launches are projected to contribute to revenue and cash proceeds in the second half of 2026.
Market Growth: The epinephrine market is expected to grow at 6%-8% annually, with Neffy expanding the market through improved refill rates, new patient adoption, and higher devices per patient.
Clinical Trials: Phase IIb urticaria trial is ongoing, with top-line data expected in mid-2026. If approved, the nasal spray product could capture over 60% of the chronic spontaneous urticaria (CSU) patient market.
Strategic Initiatives: The 'Get Neffy on Us' program is expected to drive year-round sales growth by simplifying access and reducing administrative burdens for patients and physicians.
Financial Outlook: The company expects to achieve cash flow breakeven without additional equity financing, supported by a $250 million term loan facility.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How did the Q3 performance compare to internal expectations?
A:The performance met internal expectations and exceeded analysts' expectations. Despite challenges over the summer, such as doctor burden, the company adjusted quickly with initiatives like the 'Get neffy on Us' program, which received positive feedback from physicians.
Q:Why is there a higher share among newer prescribers, and why aren't these initiatives driving similar growth among prior prescribers?
A:New prescribers tend to trial neffy with some patients before expanding usage. Existing prescribers are increasing their market share, but the overall market share dipped in summer due to a high volume of virtual renewals, which do not involve doctor visits. The company expects to benefit from virtual prescribing renewals starting next year.
Q:Can you elaborate on institutional sales, their volume, economics, and growth opportunities?
A:Management declined to provide detailed information, citing inconsistency in institutional sales and the early stage of formal marketing efforts in this area.
Q:What percentage of covered lives require prior authorizations, and what is being done to raise awareness of the online prescribing option?
A:About 50% of covered lives require prior authorizations, with 57% of commercial prescriptions not requiring them. The company is promoting the online prescribing option through updated TV commercials, email blasts, and advocacy group communications, emphasizing no cost to patients and multiple packs availability.
Q:What are the inventory levels for neffy, and how should they be considered for Q4?
A:Distributors maintain 15-20 days of inventory, adjusting for seasonality. Inventory levels are expected to decrease in Q4, contributing to lower sales compared to Q3.
Q:What portion of neffy prescriptions are tracked by IQVIA versus other channels?
A:Approximately 55% of prescriptions are filled through retail channels, with inconsistencies in IQVIA's tracking of other channels.
Q:What are the gating factors for reaching unrestricted access, and what are the timelines for adding major formularies?
A:The company is optimistic about adding CVS Caremark and other major formularies in the first half of next year. Progress is also being made with Prime and Blue Cross companies. Payers consider market growth, medical value, and cost management when making decisions.
Q:How is the U.K. launch of neffy progressing compared to Germany and the U.S.?
A:The U.K. launch is in early stages, but adoption is expected to be more like Germany due to seamless reimbursement processes and rapid access.
Q:What progress has been made in targeting pediatricians with the ALK U.S. sales force?
A:The company has reached about 20,000 physicians, including 9,000 pediatricians, with increasing share and new prescribers.
Q:What is the expected impact of the virtual prescriber program, and which demographics will benefit most?
A:The program is expected to reduce doctor burden and provide quicker access for patients, especially caregivers and parents. It eliminates waiting times and travel, making it easier for patients to obtain neffy. Doctors and patients have responded positively to the program.
Q:Review of Unclear Management Responses
A:Management avoided providing details on institutional sales, citing inconsistency and early-stage efforts in this area.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACAAI
CEO Director
HCP
IQVIA
Slide product
balance sheet
brand awareness
capture
dilution
dynamic school
epinephrine market
expansion
financing
getneffycom
hassle
improvement
increase
initiative patient
injection
investment term
launch approval
loan facility
market dynamic
market price
patient opportunity
prescriber
prescription volume
program access
refill rate
retention
round
segment Slide
shareholder
slide presentation
term loan
visit
world evidence
SPRY Transcript
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
Positive5-15
The earnings call reflects a positive outlook with strategic expansions, improved payer access, and a strong international presence. Despite some lack of clarity in management's responses, there is confidence in achieving breakeven by mid-2027 and significant market share growth. The absence of a market cap suggests a potential strong reaction, but overall, the strategic initiatives and positive guidance point to a likely positive stock price movement in the short term.
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call presents a mixed outlook. Financial performance is stable with positive revenue growth and a solid cash balance. However, challenges exist in regulatory and coverage hurdles, and SG&A expenses are high. The Q&A reveals some concerns about inventory dynamics and the unclear timeline for unrestricted access. Despite strategic initiatives and global expansion plans, the overall sentiment remains neutral due to the lack of immediate catalysts and ongoing uncertainties in coverage and market expansion.
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
Positive11-10
The company reported strong growth in neffy prescriptions and revenue, with a 2.5-fold increase in U.S. net product revenue. Despite a net loss, the financial health remains stable with significant cash reserves. The Q&A highlighted positive feedback from new initiatives and optimism about future growth through partnerships and expanded market access. While some uncertainties exist, such as reliance on a term loan and inconsistent institutional sales, the overall sentiment is positive due to revenue growth, strategic initiatives, and optimistic guidance.
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call summary and Q&A indicate strong growth in Neffy's sales and positive market reception, demonstrated by a 64% increase in revenue and increased prescriptions. The DTC campaign is expected to further drive growth. However, there is some concern about the ceiling for commercial coverage without prior authorization. Despite this, the overall sentiment is positive due to strong financial performance and optimistic future guidance.
SPRY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
